COSTS AND QUALITY OF LIFE IN CLINICAL TRIALS OF HEART FAILURE IN THE US

U. Silas,¹ J. Hafermann, ¹ A. Bosworth Smith,¹ A. Veloz,² R. Saunders¹ (1) Coreva Scientific GmbH & Co KG, Koenigswinter, NRW, Germany; (2) ZOLL Medical, Pittsburgh, PA, USA

OBJECTIVE

- To assess whether clinical trials for non-pharmaceut interventions are collecting quality of life and cost da
- This area of product evaluation is becoming more period regulations for medical technologies progress towar pharmaceuticals.
- This case study is performed in the US heart failure

METHODS

 A systematic literature review (Prospero registration) CRD42023410084) was conducted in PubMed and identify literature published between 2008 and 2023.



Figure 1 PRISMA diagram of the systematic literature review

| tical ata ertinent as d those for | The inclusion criteria were randomised clinical trials with patients in the US over the age of 18 who fulfilled all following criteria: Diagnosed with heart failure in the last 12 months Intervention of heart failure monitoring Comparator of watchful waiting | | |
|--|---|---|-----------------------|
| population. | RESULTS | | |
| | Searches identified 2,248 unique abstracts across the two databases. | | |
| EMBASE to | After title and abstract screening and full-text review, 31 studies were included for analysis. (Figure 1) | | |
| | Two of 31 studies (6.5%) reported on both quality of lfe and costs. (Figure 2) | | |
| d as duplicates (n=688) | Questionnaire bein Four studies (12.9% collected being tota to USD 52,000 (20) Heterogeneity in the Table 1 Quality of life | ng used equally. (Table 1) 1%) reported on costs, with the most commonly cal cost of care, which ranged from USD 11,000 022 USD) per patient. he type of costs collected was evident. fe and/or cost reporting in the included studies | |
| n=2,165) | Publication | Quality of life measure | Costs reported |
| | Abraham 2011 ¹ | MI HEQ | No |
| xcluded | Bekelman 2015 ² | KCCQ | No |
| (n=52) | Blum 2014^3 | MI HEQ & SE-26 | Yes |
| on 31 | Dorsch 2021 ⁴ | MI HEO & SCHEI | No |
| tor 5 | Javaram 2017 ⁵ | KCCO | No |
| 4 | Johnson 2022 ⁶ | KCCO | No |
| pe 1 | l indenfeld 20217 | | No |
| 7 | Madinan 2021 | KCCO | No |
| | $Ona 2016^9$ | | No |
| | Schwarz 200810 | | Vec |
| | Soron 200011 | | Vee |
| | Tompking 201012 | | Voc |
| | | | |
| | IVIL HECJ' IVIINNESOTA IIVINA | with neart failure duestionna | aire KUCU Kansas Citv |

ISPOR 2024 | MAY 5-8, 2024 | ATLANTA, GA, USA

INCLIFY. MILLIESULA IMILY WILL HEALT AND E QUESUULIANE, NOUV. NAIISAS OLY Cardiomyopathy Questionnaire, SF-36: 36-item short form survey, SCHFI: Selfcare heart failure index: EQ-5D: EuroQol 5-dimension quality of life questionnaire

CONCLUSION

- design for medical technologies.
- population.



References

- BMC Cardiovasc Disord. 2013 Jul 9;13:49.
- JMIR Mhealth Uhealth. 2021 Dec 7;9(12):e26185.
- Controlled Trial. JMIR Cardio. 2022 Mar 21;6(1):e33286.
- 11;398(10304):991-1001.
- Serv Q. 2013;32(1):57-74.
- (BEAT-HF) Randomized Clinical Trial. JAMA Intern Med. 2016 Mar;176(3):310-8.
- Nurs. 2008 Winter;23(1):18-26.
- discussion 322-3.

Disclosure

US, JH, and ABS are employees and RS is the owner of Coreva Scientific GmbH & Co KG, all of whom received consultancy fees for this research. AV is an employee of ZOLL Medical. The research was funded by ZOLL Medical.

• In heart-failure clinical trials of non-pharmaceutical interventions, costs and quality of life are infrequently reported

SA37

• There is room for improvement in this area of clinical trial

• At this time, health-economic analysis of single trials for medical technology will remain rare in the heart-failure

Costs & Quality of Life Only costs Only Quality of Life

Neither cost nor Quality of Life

Figure 2 Investigated studies including costs, quality of life, or both

Abraham et al. FAST Study Investigators. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail. 2011 Mar-Apr;17(2):51-5. Bekelman et al. Patient-centered disease management (PCDM) for heart failure: study protocol for a randomised controlled trial.

3. Blum K, Gottlieb SS. The effect of a randomized trial of home telemonitoring on medical costs, 30-day readmissions, mortality, and health-related quality of life in a cohort of community-dwelling heart failure patients. J Card Fail. 2014 Jul;20(7):513-21. Dorsch et al. The Effects of the ManageHF4Life Mobile App on Patients With Chronic Heart Failure: Randomized Controlled Trial.

5. Jayaram et al. Impact of Telemonitoring on Health Status. Circ Cardiovasc Qual Outcomes. 2017Dec;10(12):e004148. Johnson et al. Developing and Implementing an mHealth Heart Failure Self-care Program to Reduce Readmissions: Randomized

Lindenfeld et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 Sep

Madigan et al. Home health care with telemonitoring improves health status for older adults with heart failure. Home Health Care

Ong et al. Better Effectiveness After Transition–Heart Failure (BEAT-HF) Research Group. Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure

10. Schwarz et al. Telemonitoring of heart failure patients and their caregivers: a pilot randomized controlled trial. Prog Cardiovasc

11. Soran et al. A randomized clinical trial of the clinical effects of enhanced heart failure monitoring using a computer-based telephonic monitoring system in older minorities and women. J Card Fail. 2008 Nov;14(9):711-7. 12. Tompkins C, Orwat J. A randomized trial of telemonitoring heart failure patients. J Healthc Manag. 2010 Sep-Oct;55(5):312-22;